Active, not recruitingPhase 3NCT05280548
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & Operations Clinical Sciences and OperationsSanofi
- Intervention
- Venglustat (GZ402671)(drug)
- Enrollment
- 104 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2022 – 2026
Study locations (20)
- University of Alabama -The Kirklin Clinic- Site Number : 8400010, Birmingham, Alabama, United States
- University of California Los Angeles Medical Center- Site Number : 8400008, Los Angeles, California, United States
- Emory University School of Medicine - Atlanta- Site Number : 8400009, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005, Chicago, Illinois, United States
- Maryam Banikazemi, MD- Site Number : 8400001, Hawthorne, New York, United States
- Renal Disease Research Institute- Site Number : 8400012, Dallas, Texas, United States
- University of Utah Health Hospital- Site Number : 8400006, Salt Lake City, Utah, United States
- Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004, Fairfax, Virginia, United States
- Investigational Site Number : 0400001, Graz, Austria
- Investigational Site Number : 1240003, Calgary, Alberta, Canada
- Investigational Site Number : 1240006, Edmonton, Alberta, Canada
- Investigational Site Number : 1240002, Vancouver, British Columbia, Canada
- Investigational Site Number : 1240005, Toronto, Ontario, Canada
- Investigational Site Number : 1560002, Beijing, China
- Investigational Site Number : 1560005, Beijing, China
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05280548 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.